BioCentury
ARTICLE | Clinical News

QIMR reports updated Phase I data for MS candidate

December 1, 2017 9:39 PM UTC

Atara Biotherapeutics Inc. (NASDAQ:ATRA) said QIMR Berghofer Medical Research Institute (Brisbane, Australia) reported updated data from a Phase I trial in 10 patients with primary progressive multiple sclerosis (PPMS) and secondary progressive MS (SPMS) showing that 4 escalating doses of autologous ATA190 over 6 weeks led to clinical improvements in 6 patients. In 5 patients with ≥7% Epstein-Barr virus reactivity, the candidate improved Expanded Disability Status Scale (EDSS) score in 3 patients. In 4 patients with ≤3% Epstein-Barr virus reactivity, autologous ATA190 led to 1 mild clinical improvement, 1 case of EDSS worsening and 2 cases of no change. Autologous ATA190 reduced fatigue in responders and was well tolerated with no significant treatment-related adverse events reported.

Data were presented at the joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) meeting in Paris...